Clinical Trial News Archive
Get news by email or subscribe to our news feeds.
News Archive for November 2007
November 1, 2007
- Orexigen Therapeutics to Present Data Supporting Novel, PreClinical Drug Combination for Schizophrenia
- Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
- Results of TRIUMPH-1 Trial of Viveta in Pulmonary Arterial Hypertension to Be Announced Before Market Open on Thursday, November 1, 2007
- Potent Hepatitis C Virus Inhibitors Show Efficacy and Potential for Once Daily Dosing in Preclinical Studies
- BioGeneriX and Neose to Host Conference Call to Present GlycoPEG-GCSF Phase I Data
- Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
- Argos Therapeutics Presents Positive Data on its Personalized Cancer Immunotherapy Programs at ISTBC Meeting
- Procrit (Epoetin Alfa) Data to Be Presented at American Society of Nephrology Annual Meeting
- Incyte Reviews Positive Proof-of-Concept Clinical Results Achieved During the Third Quarter; Cites Continued Progress in Multiple Drug Development Programs; Announces Third Quarter Financial Results
- Proteon Therapeutics to Present at Annual Meeting of American Society of Nephrology in San Francisco on November 2, 2007
- BioDelivery Sciences International Reveals Additional Details Regarding BEMA LA
- UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
- Abbott Researchers Target Neuronal Nicotinic Receptors for Treatment of Pain and Cognition
- Trial Shows Minocycline Has a Harmful Effect on Patients with Motor Neuron Disease
- Mayo Clinic Study Shows Drug Could Effectively Treat, Prevent the Spread of Breast Cancer
- New Data Presented at UEGW Confirm Effectiveness and Safety of Resolor for Patients with Chronic Constipation
- Triumph-1 Trial of Viveta in Pulmonary Arterial Hypertension Meets Primary Endpoint
- Obesity Common in Children with Heart Disease
- Endo announces update on Phase III-program for Orexo's pain product Rapinyl
- GlobeImmune Announces Presentation of Additional Phase 1b Hepatitis C Results at American Association for the Study of Liver Diseases 2007 Annual Meeting
- Hythiam's Prometa Treatment Program Demonstrates Statistically Significant Reduction in Methamphetamine Cravings in Randomized, Double-Blind Placebo-Controlled Study
- Protox Announces Positive Final Data from Prostate Cancer Study
- Common Medications Provide Equal Blood Pressure Control
November 2, 2007
- Memory Pharmaceuticals Announces Positive Phase 2a Results for MEM 3454 in Alzheimer's Disease
- ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
- Phase II Study Shows that Nitazoxanide Significantly Improves Response to Standard of Care in Patients with Chronic Hepatitis C
- Data from Completed Phase 1 Studies of Novel Adenosine A2b Antagonist CVT-6883 Show Safety, Tolerability and Potential Utility in Chronic Pulmonary and Inflammatory Diseases
- First Studies Demonstrating Greater than Sixty Percent Sustained Viral Response Rates with Half the Standard Treatment Duration in Genotype 1 Chronic Hepatitis C Patients
- IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients
- Treatment with Pegasys/Copegus Provides Hope for Hepatitis C Patients Whose Infection Did Not Initially Respond to Peg-Intron/Ribavirin
- Roche's Investigational Polymerase Inhibitor, Combined with Pegasys and Copegus, Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
- Gilead Announces 48-Week Data from Two Pivotal Phase III Studies Evaluating Viread For the Treatment of Chronic Hepatitis B
- ACADIA Pharmaceuticals to Present Preclinical Data on Its Advanced Schizophrenia Programs at the 37th Annual Meeting of the Society for Neuroscience
- Progen to Present Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
- Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C
- IDM Pharma Announces Data Presentation From Mifamurtide (L-MTP-PE) Compassionate Use Program
- IDM Pharma Announces IDM-2101 Updated Phase 2 Results Show Treatment Well Tolerated With Positive Survival Trend in Lung Cancer Patients
- IDM Pharma Announces Updated Phase 2 UVIDEM Results Showing Durable Disease Control and Tolerability in Advanced Melanoma Patients
- New clinical results support telomerase vaccination in breast cancer
- Ninety-one Percent of Baraclude (entecavir) Treated Patients in a Four-Year Cohort Demonstrated Virologic Suppression to Undetectable Levels
- St. Jude Finds Anti-Leukemia Drug Increases Patient Fatigue
- Flutiform - Results of Safety Study
- BioInvent and ThromboGenics Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
- Arpida Presents Data on Iclaprim at Scientific Congress in Germany
- Excellent Results Received from GeoVax's Full-Dose HIV/AIDS Vaccine Trial
- First Studies Demonstrating Greater than Sixty Percent Sustained Viral Response Rates with Half the Standard Treatment Duration in Genotype 1 Chronic Hepatitis C Patients
November 5, 2007
- Sangamo BioSciences Presents Postive Data Showing Pain Reduction by Novel ZFP Therapeutic at Society for Neuroscience Meeting
- ZIOPHARM Presents Positive Phase II Data for ZIO-201 in Soft Tissue and Bone Sarcomas at Connective Tissue Oncology Society (CTOS) Annual Meeting
- Osteologix Announces Positive Phase II Study of Its Investigational Osteoporosis Drug, NB S101; Trial Meets Primary Endpoint
- Human Genome Sciences Announces Full Presentation of Quality-of-Life Results From Phase 2b Trial of Albuferon for Hepatitis C
- Human Genome Sciences Announces Presentation at AASLD of Results of Phase 2b Trial of Albuferon(R) for Chronic Hepatitis C
- Positive Results From Peregrine Pharmaceuticals' Bavituximab Phase l HCV Trial Presented at AASLD Meeting
- New Data Examines the Effect of Adding a Statin to Optimized Treatment for Patients with Advanced Heart Failure
- Nventa Presents HspE7 Data at International HPV Conference
- Medivation's MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
- Phase 2 Trial Results for Exelixis' XL784 Presented at the 2007 American Society of Nephrology Conference
- Gilead Announces Phase I Data for GS 9190, An Investigational Compound for the Treatment of Chronic Hepatitis C
- MannKind Announces Positive Results from a Phase 1a Study of a GLP-1 Formulation
- Affymax Announces Hematide Successfully Restores Hemoglobin in Patients with Pure Red Cell Aplasia (PRCA)
- Daiichi Sankyo, Lilly Announce New Prasugrel Head-to-Head Phase III Study Against Clopidogrel
- New Data Presented on Gardasil, Merck's Cervical Cancer Vaccine, in Women Through Age 45
- Abbott's Investigational Simcor Offers Comparable LDL Lowering to Simvastatin and Significantly Raises HDL and Lowers Triglycerides in Phase III Study
- Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
- Positive Results from CVBT's Phase I No-Option Heart Disease Clinical Trial Will Be Presented at the American Heart Association's Annual Meeting
- New Data Examines The Effect Of Adding A Statin To Optimised Treatment For Patients With Advanced Heart Failure
- Synvista Collaboration Demonstrates in Preclinical Studies the Mechanism for Defective Cholesterol Transport in Patients with Diabetes
- Treatment with PEGASYS/COPEGUS Provides Hope for Hepatitis C Patients Whose Infection Did Not Initially Respond to Peg-Intron/Ribavirin
- Suven Life Sciences Presenting Pre-clinical Data of their NCEs at Society for Neuroscience Annual Meeting, SFN-2007 at San Diego, USA
- Reported to the American Heart Association Scientific Sessions: Newly Discovered Heart Wall Abnormality May Predict Risk of Stroke Associated with Patent Foramen Ovale, AGH Cardiologists Report
- New Lipitor Data Analyses from Landmark Ideal and SPARCL Trials to Be Presented at Upcoming Annual Scientific Sessions of the American Heart Association
- At TCT 2007, Cappella Demonstrates Procedural Advantages and Clinical Benefits of Its Technology in Treating Coronary Bifurcations
- Ranexa Significantly Reduces Incidence of CV Death, MI or Recurrent Ischemia in MERLIN TIMI-36 Patients With Elevated BNP
- Metabasis Presents Preclinical Results at AASLD Showing MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, Reduces Liver Fat
- Seattle Genetics Reports Positive Phase I Data with SGN-35 in Hodgkin Lymphoma
- Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
- Advanced Cell Technology and the Casey Eye Institute at Oregon Health & Science University Present Results of Functional Studies for RPE Program at Neuroscience 2007
- New Study Provides Scientific Evidence That DermaLastyl Face Cream Reduces Wrinkles
- Cleveland Clinic Study Suggests Failure of HDL-Raising Drug Torcetrapib is Likely Compound Specific
- SPP100 (tekturna/rasilez) Decreases Proteinuria in Diabetic Patients
- Conatus Pharmaceuticals Reports Positive Results of CTS-1027 in Multiple Preclinical Studies of Liver Disease
- Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting
- Pooled Analysis of Long-Term Data Suggests Cypher Sirolimus-Eluting Coronary Stent Provides Sustained Clinical Benefits in Patients with Coronary Artery Disease Compared to Bare Metal Stents
- Preschoolers with Three or More Coexisting Disorders Show No Response to ADHD Medication Treatment
- Pipex Pharmaceuticals' Anti-Copper Coprexa Demonstrates 40% Reduction of Insoluble Amyloid Beta in Animal Models of Alzheimer's Disease
- Avigen's AV411 Shows Promising Initial Results for Neuropathic Pain Phase IIa Data Presented At the International Conference On the Mechanisms and Treatment of Neuropathic Pain
- Avigen Presents At the 37th Annual Meeting of the Society for Neuroscience Presentation of AV650 Phase I Data Shows No Evidence of Sedation
- CorMedix Studies Show That Removing 'Toxic' Iron Could Slow Progression of Chronic Kidney Disease
November 6, 2007
- Merck's Investigational Extended-Release Niacin/Laropiprant (CORDAPTIVE(TM)) Coadministered with Simvastatin Had Significant Additive Effects on LDL-C, HDL-C and Triglycerides in Phase III Study
- Addition of Integrilin (Eptifibatide) to Bivalirudin Plus Standard of Care Inhibits Platelet Aggregation in Patients Undergoing Elective Coronary Stenting
- Shire Announces Results of Fosrenol Study in Pre-Dialysis CKD Stage 3 & 4 Patients
- BioLineRx Presents BL-1040 Data at the American Heart Association Scientific Sessions 2007
- MacroChem Announces Positive Interim Phase 2 Data for EcoNail in the Treatment of Onychomycosis
- Poniard Pharmaceuticals Announces Positive Preliminary Bioavailability Data From Ongoing Phase 1 Trial of Oral Picoplatin in Patients With Solid Tumors
- German and U.S. Researchers Show TB4's Cardioprotective Effects in Ischemia-Reperfusion Injury
- Neurogen Announces Adipiplon Preclinical and Clinical Data to Be Presented at Neuroscience 2007
- Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diabetes
- Data Presented at the American Heart Association Scientific Sessions 2007 Demonstrated Increased HDL with Actos (pioglitazone HCl) Slowed the Progression of Carotid Intima-Media Thickness in Patients with Type 2 Diabetes
- A Life Sciences Renaissance: 100th Peer-Reviewed Publication Enabled by 454 Sequencing
- Results from Phase 1 Study of AVEO's Novel Triple VEGF Receptor Inhibitor AV-951 Show 100% of Renal Cell Cancer Patients Achieved Partial Response or Stable Disease
- Sanofi Pasteur Presents Positive Results of Tetravalent Dengue Candidate Vaccine
- Neurogen Announces Aplindore Preclinical Data to Be Presented at Neuroscience 2007
- AVI BioPharma to Present on NEUGENE Countermeasures to Biological Threats at U.S. Department of Defense 2007 Biodefense Research Conference
- Can-Fite: CF101 May Be Effective for the Treatment of Crohn's Disease
- VIA Pharmaceuticals Presents Data at American Heart Association Meeting Showing VIA-2291 Significantly Reduces Inflammation in Preclinical Model of Atherosclerosis
- Ranexa Significantly Reduces Ischemia in Women in MERLIN TIMI-36 Study
- World Think Tank on Type 1 Diabetes Meets in Miami
- Photo: Scientists Complete Genome Sequence of Fungus Responsible for Dandruff, Skin Disorders
- This Book Meets The Long Awaited Need For A Comprehensive Overview Of The Biological Role Of High Density Lipoproteins
- Acusphere Announces Data Demonstrating Imagify Perfusion Stress Echo is Well-tolerated and as Effective as Nuclear Perfusion Imaging for Evaluating Chest Pain Patients at Risk for Heart Attack
- Lipitor Provides Greater Benefit Compared to Simvastatin in Patients with a History of Heart Attacks Who Have Had Subsequent Cardiovascular Events
- New Study Reveals MRSA Bacteria Common Among Pigs and Farm Workers
- Presentation of Phase IIa Results for Cytos Biotechnology's Hypertension Vaccine at the American Heart Association Scientific Sessions 2007
- Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at Society for Neuroscience Meeting
- Micromet's BiTE Antibodies Reveal Unique Mode of Action
- Millennium Announces MLN1202 Significantly Reduced Marker of Systemic Inflammation and Identifies Genomic Biomarker For Responders
- Encysive Pharmaceuticals Announces Presentation of Sitaxsentan Data in Eisenmenger Syndrome At AHA Meeting
November 7, 2007
- LifeCycle Pharma Announces Positive Results From Head-to-Head Clinical Trial of LCP-Tacro Versus Advagraf For the Prevention of Organ Rejection After Transplantation
- BioGeneriX and Neose Technologies Announce Positive Data from Two Phase I Studies of GlycoPEG-GCSF
- NicOx' Naproxcinod ABPM Data Presented at American Heart Association
- ARCA Discovery Announces Data Demonstrating Potential for Bucindolol as Targeted Therapy in Heart Failure, Atrial Fibrillation, and Ventricular Arrhythmia
- Data Show Geron's Cell-Based Therapeutic for Spinal Cord Injury Survives and Exhibits Remyelination for at Least Nine Months Following Injection
- New Clinical Study Shows Limbrel as Effective as Naproxen for Knee Osteoarthritis
- AlphaRx's Vansolin On Track To Enter Human Trials in '08
- OctoPlus Presents Positive Phase IIa Study Results for Locteron in Hepatitis C at AASLD Conference
- New Findings Provide Insight into Treatment of Hypertension in Mexican Americans
- A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
- COURAGE Sub-study: PCI Outperforms Drugs-Only
- Raven to Present Updated Phase 1 Clinical Study Results of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas
- Study Shows Tekturna, the First and Only Approved Direct Renin Inhibitor, Reduces a Key Marker of Heart Failure Severity
- BRIGHT Results Show Less Pain and Higher Patient Satisfaction with Betaseron than with Rebif
- Presentation of Phase IIa Results for Cytos Biotechnology’s Hypertension Vaccine at the American Heart Association Scientific Sessions 2007
- Medication Does Not Appear to Improve Symptoms or Outcomes for Patients with Acute Heart Failure
- Study Shows Vernakalant Hydrochloride is Effective in Conversion to Normal Heart Rhythm in Atrial Fibrillation Patients Following Cardiac Surgery
- Nabi Biopharmaceuticals Announces Successful Completion of NicVAX Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
- Cost-Effectiveness Study Supports Use of EUFLEXXA by Rheumatologists for Pain Relief in Patients with Knee Osteoarthritis
- New Clinical Data Show Solvay’s Fenofibrate Cuts Risk of Main Causes of Vision Loss in Patients with Type 2 Diabetes
- SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients
- Fresenius Medical Care Announces: Continued Positive Data from CARE-2 Database
- GlobeImmune Announces Presentation of Results from a Randomized Phase 1b Study of the GI-5005 Tarmogen in Patients with Chronic Hepatitis C Infection
- New Data Illustrates Variances in the Use of Evidence-Based Heart Failure Treatments
- New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's Crestor (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
- Rifalazil Trial (PROVIDENCE-1) Fails to Provide Significant Clinical Benefit in Patients With Peripheral Arterial Disease
- Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
- CHW Researcher Presents Results of ACT-Sponsored Trial Demonstrating Efficacy of ACT Myoblast Therapy for Heart Failure at AHA Meeting
- Data from STEP Study Presented at Open Scientific Session Confirm Merck's Investigational HIV Vaccine was not Effective
- Advanced Cell Technology Announces 12-Month Results of Myoblast Therapy Trial
- Statement of Anthony S. Fauci, M.D., Director National Institute of Allergy and Infectious Diseases On the Release of New Data from the HVTN 502 (STEP) HIV Vaccine Study
- Scientists Compare Twelve Fruit Fly Genomes
- Sangamo BioSciences Announces ZFP Therapeutic Data From Nerve Regeneration Program at Society for Neuroscience Meeting
- Leukemia Drug Proves Safe and Effective Over the Long Term
November 8, 2007
- Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis
- Genasense Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium
- Milnacipran Demonstrated Significant Improvement in Pain and the Core Symptoms of Fibromyalgia Syndrome, Data Show
- VistaGen CEO to Present Overview of Recent Stem Cell-Based Drug Discovery and Development Advances at Society of Biomolecular Sciences Symposium
- CV Therapeutics' Selective Adenosine A1 Agonist Tecadenoson Shows Synergistic Effect with Ultra Low Dose Beta Blocker in Preclinical Atrial Fibrillation Model
- Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis
- Two Pivotal Phase III Studies for Roche's Actemra (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
- Immunosyn Corporation Releases SF-1019 Study Results
- LifeCycle Pharma Announces Positive Results From Head-to-Head Clinical Trial of LCP-Tacro Versus Advagraf For the Prevention of Organ Rejection After Transplantation
- Medarex Announces Presentations on UltiMAb Antibodies at 71st Annual Meeting of the American College of Rheumatology
- Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417 for Symptoms of Bipolar Disorder
- Abbott Research Demonstrates Viability of Combining Antibody Functions to Target Two or More Disease-Causing Processes
- MedImmune Presents Data from Its Advancing Inflammatory Disease Portfolio at 71st Annual Meeting of The American College of Rheumatology
- Lodotra Shows a Sustained Reduction of Morning Stiffness in Patients with Rheumatoid Arthritis Treated with Lodotra for 12 Months
- New Actemra Data Shows Significant Benefit for Patients Suffering From Rheumatoid Arthritis
- Abbott Study Examines Rates of Uveitis (Inflammation of the Eye) in Ankylosing Spondylitis Patients Treated with Humira (adalimumab)
- Genasense Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium
- Cimzia (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
- Fenofibrate - First Lipid Modifying Agent Shown to Protect Diabetic Eye
- Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417 for Symptoms of Bipolar Depression
- New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings
- New Data Show That Half of Patients with Active Early Rheumatoid Arthritis Achieved Clinical Remission at One Year When Treated with Enbrel (etanercept) Plus Methotrexate
- MediQuest Announces Positive Results from Phase III Study
November 9, 2007
- Biogen Idec's Baminercept, the First Lymphotoxin-(beta) Pathway Inhibitor in Development, Shows Promise in Patients with Rheumatoid Arthritis
- Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B in Patients with Active Systemic Lupus Erythematosus
- Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis
- Cougar Biotechnology Presents Positive CB7630 Phase II Data at Chemotherapy Foundation Symposium
- Five-Year Data Demonstrate Long-Term Efficacy and Safety with Orencia (abatacept) in Adults with Rheumatoid Arthritis Who had an Inadequate Response to Methotrexate
- Inspire Announces Oral Presentation of Phase 2 Epinastine Nasal Spray Data at American College of Allergy, Asthma & Immunology Meeting
- Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium
- Pharmexa A/S (DK) - Promising clinical results from new HIV vaccine
- Sirtris Scientific Advisory Board Member Describes a Novel Endogenous SIRT1 Activator
- New Phase III Trial Results for Rivaroxaban to be Presented at the 49th Annual Meeting of the American Society of Hematology
- Biogen Idec's Baminercept, the First lymphotoxin-b PATHWAY Inhibitor in development, Shows Promise in Patients with Rheumatoid Arthritis
- Rigel R788 Raises Platelet Counts in Immune Thrombocytopenic Purpura (ITP) Patients in Phase 2 Study
- Alexion Pharmaceuticals to Present Data on Soliris (Eculizumab) and PNH at the 2007 American Society of Hematology (ASH) Annual Meeting
- Genmab to Present Zanolimumab and Ofatumumab Data at ASH
- Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer - Nov 9, 2007
November 12, 2007
- Hollis-Eden Pharmaceuticals Presents Data on Apoptone and Potential Role of Adrenal Steroid Hormones for the Treatment of Cancer
- ImmuneRegen BioSciences' Viprovex Demonstrates Further Evidence for Effectiveness Against Influenza Virus, Including Avian Flu
- NanoViricides Drug Effectiveness Confirmed Against Rabies and Influenzas
- Nuvelo Announces Presentations on Alfimeprase, rNAPc2, and the Leukemia TherapeuticS Program at the American Society of Hematology 49th Annual Meeting
- Development of Dyax's Patient Reported Outcome for the Treatment of Hereditary Angioedema Presented at ACAAI Meeting
- Lev Presents Significant Data from Pivotal Phase III Trial of Cinryze in Acute Treatment of Hereditary Angioedema at ACAAI Meeting
- New Data Presented at ACAAI Informs on the Safety and Efficacy of Nasacort AQ Nasal Spray in a Trial of Children Aged 2-5 Years Old with Year-Round Allergic Rhinitis
- New Data Shows Veramyst Effectively Treats Symptoms of Perennial Allergic Rhinitis
- VistaGen Publishes Preclinical Data Supporting the Therapeutic Potential of AV-101 for Parkinson's Disease
- L-Proline Stabilizer Used in the Intravenous Immunoglobulin Product Privigen Shows No Neurological Side Effects Compared with Currently Used Stabilizers
- Major Phase 3 Trial Shows Zevalin Extends Progression-free Survival in One of the Most Common Types of Lymphoma
- Dynavax Presents New Analysis of Tolamba Data at ACAAI Meeting
- New Hope in Immunodeficiency Treatment for Improved Tolerability and Convenience in the use of Immune Globulin Intravenous (Human) 10% Liquid (Privigen)
- Akela Pharma Announces Final Positive Results from its Growth Hormone Releasing Hormone (GHRH) Phase II Trial
- Celsion Corporation Announces Liver Phase I Abstract Accepted for Oral Presentation at 8th World Congress of IHPBA
- VGX Pharmaceuticals' SynCon Pandemic Flu Vaccine Protects Against A Lethal Challenge of Live Virus in Pre-Clinical Animal Models
- Eliminating Influence of Hyperactive Genes That Help Regulate Cell Development Shows Potential as Additional Target Therapy for Chronic Myelogenous Leukemia
- Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with Orencia (Abatacept)
- ISTA Pharmaceuticals Presents Results from Two Phase III Clinical Trials of Xibrom QD (Once-daily) Formulation at the American Academy of Ophthalmology Annual Meeting
- NicOx’ Naproxcinod Phase 3 Results Presented at American College of Rheumatology
- Media Advisory - New Study Shows Reduction in Anti-Depressant Withdrawal Symptoms
November 13, 2007
- Journal of Neuroimmunology Publishes Study Results Showing That Geron's Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
- Isis Reports New Data for Mipomersen in Routine High Cholesterol Patients and Provides Cumulative Safety Summary
- New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin in Preclinical Cancer Models
- NeoVista, Inc. Presents New Data on Its Novel Wet AMD Therapy at AAO
- Preclinical Data Published in Cancer Science Show AVEO's Novel Oral EGFR Inhibitor AV-412 Effective in Drug-Resistant Cancers
- Tumor Eradication Article Published by Cancer Research
- Diabetes Rates Are Increasing Among Youth
November 14, 2007
- Study Shows Organon's Asenapine Demonstrates Efficacy and Tolerability in Treating Acute Schizophrenia
- Nymox Reports Completion of Large New 2 Year Follow-up Study of NX-1207 for BPH
- Scientists Zero in on the Cellular Machinery that Enables Neurons to Fire
- M. D. Anderson Researchers Identify Tumor- Suppressor Gene for Lung Cancer
November 15, 2007
- Introgen Therapeutics Highlights Summary Advexin Data at the Third International Workshop on Mutant p53 and the Symposium on Li-Fraumeni Syndrome
- Pramlintide and Leptin Combination Treatment Demonstrates 12.7 Percent Weight Loss in 24-Week Clinical Obesity Study
- Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
- Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases
- The New England Journal of Medicine Publishes First Clinical Results for MedImmune's Chitinase-like Protein YKL-40 in Patients With Asthma
- Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases Safety Analysis Shows Good Tolerance with No Serious Adverse Reactions
- New England Journal of Medicine Study Shows Erbitux Improves Survival in Advanced Colorectal Cancer
- New Data for Menveo Vaccine Show Excellent Immune Response and Broad Protection for Infants Against Meningococcal Meningitis
- Forteo Increased Spine Bone Mineral Density in Patients with Glucocorticoid-Induced Osteoporosis
- New Anemia Measure Predicts Risk of Death in Dialysis Patients
- Oramed Pharmaceuticals Successfully Completes Animal Studies for Phase 1B Clinical Trials Of Its Oral Insulin Capsule
- NCI Researchers Uncover Unusual Association Between Cell Survival Proteins and Ovarian Cancer Aggressiveness
- Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings
November 16, 2007
- ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
- Thallion Announces Positive Safety and Efficacy Data From ECO-4601 Phase I/II Trial
- Genmab to Present HuMax-IL8 Pre-Clinical Data
- Study Shows Weight-Loss Drug Rimonabant is Associated with Severe Adverse Psychiatric Events
November 19, 2007
- Hollis-Eden Pharmaceuticals Presents Data Demonstrating Triolex Provides Benefit in Additional Animal Model of Rheumatoid Arthritis
- Avastin Shows Encouraging Results in Phase II Study in Patients With the Most Aggressive Form of Brain Cancer
- Affitech-Identified Fully Human Anti-VEGF Antibody Candidate is as Effective as Avastin in Preclinical Cancer Models
- Data on Avicena's Drug Candidate HD-02 Presented at the 2007 World Congress on Huntington's Disease
- Raven Announces Phase 1 Clinical Trial Results of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas
- Avastin Shows Encouraging Results in Phase II Study in Patients With the Most Aggressive Form of Brain Cancer
- Pharmexa Provides Update on the HeptoVax Trial of GV1001 In Liver Cancer
- TransMolecular Reports Positive Phase 2 Data from Study of (131)Iodine Radiolabeled TM-601 in Recurrent Glioma
- Early Results of Phase 2 Trial of Perifosine (KRX-0401) for the Treatment of Recurrent Malignant Gliomas Presented at the 12th Annual Scientific Meeting of Society for Neuro-Oncology
- The Aethlon Hemopurifier Reverses Immune Suppression in Cancer
- Solagran Limited's Bioeffectives to be Used to Treat Alzheimer's Patients and Alcoholics in Russia
November 20, 2007
- Cytos Biotechnology presents encouraging phase IIa study results for its melanoma vaccine CYT004-MelQbG10
- Combining Medications Often Best Strategy to Battle Rheumatoid Arthritis
- New Phase 2 Study Shows That Liraglutide Leads to Significant Weight Loss in Obese People
November 21, 2007
- Brostallicin Trial Data Demonstrates Encouraging Anti-tumor Activity in Patients With Chemotherapy-Resistant Cancers
- Neose Announces Data Presentations on GlycoPEGylated Factor VIIa at the American Society of Hematology Annual Meeting
- Positive Outcome of Drug-Drug Interaction Trial With Intravenous Iclaprim
- Vertex's Collaborator Merck Suspends Patient Enrollment in Clinical Trials of MK-0457 (VX-680) Pending Full Analysis of Clinical Data
November 26, 2007
- Drug Combination Effective Against Multiple Myeloma, Researchers Show
- Isotechnika Inc. completes critical study
- CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting
- Nereus Pharmaceuticals to Present Research at the Annual Meeting of the American Society of Hematology
- New Data to Support Velcade (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
- Oral Drug Sets a New Survival Standard for Bone Marrow Cancer
- ImmunoGen, Inc. Announces Presentations on Clinical-Stage Compounds at ASH Annual Meeting
- CytRx Reports Favorable Safety and Tolerability Results from High Dose, 28-Day Clinical Trial with Arimoclomol
- Novelos Therapeutics to Webcast Investor and Analyst Day on Nov 27th in NYC
- Cardiome Updates Guidance
- Two Major Phase III Studies Report Oral Revlimid (Lenalidomide) Plus Dexamethasone Shows Increased Overall Survival Advantage to Dexamethasone Plus Placebo in Previously Treated Multiple Myeloma Patients in The New England Journal of Medicine
- NovaBay Announces Positive Phase I Study Results with Its Lead Aganocide Compound
- AVANT's Partner, GlaxoSmithKline, Announces New Data Published in The Lancet Show That Rotarix Provides Sustained and Broad Protection During the First Two Years of Life
- Kiadis Pharma Presents ATIR and Rhitol Data at ASH and NIH Presentation on ATIR at ASH
- New Data Published in The Lancet Show GSK's Rotarix Offers Protection Against the Most Common Circulating Rotavirus Types
- Moffitt Cancer Center Takes Part in Newly Published Study in This Week's New England Journal of Medicine
- Updated Revlimid (Lenalidomide) Plus Dexamethasone Data in Previously Treated Multiple Myeloma Reported in The New England Journal of Medicine
- The International Myeloma Foundation Says Revlimid Extends Survival with Positive Implications for a Wide Range of Blood Cancers
- NCI Researchers Identify Novel Mechanism for Spread of Sarcoma Tumors
- SIGA Chief Scientific Officer, Dr. Dennis Hruby, to Present ST-246 Progress and Human Clinical Safety Study Data to The World Health Organization (WHO)
- CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH for Treatment of Hereditary Angioedema
- VasoGenix Pharmaceuticals Presents Data Related to CGRP (Calcitonin Gene Related Peptide) for Heart Failure Patients
November 27, 2007
- Osiris Therapeutics Announces Positive One Year Data from Chondrogen Trial for Knee Repair
- Treating Depression Prolongs Life for Older People with Diabetes
- Cell Therapeutics, Inc. Plans to Submit sBLA for Zevalin Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008
- Dynavax Reports Progress in Lupus Program With Inhibitor of TLR7 and TLR9
- Study Shows Cholera Can be Controlled With Oral Vaccines
- VioQuest Pharmaceuticals Announces Presentation on VQD-002 at the Upcoming American Society of Hematology 49th Annual Meeting
- Eurand Completes Bioavailability Study of Zentase
- San Diego Company Formed Around Breakthrough in Stem Cell Reprogramming in Primates
- EPIX Pharmaceuticals to Present at CBI's Alzheimer's Drug Development Summit
- Gemin X Announces Publication of Unique Mechanism of Action of Obatoclax in Proceedings of the National Academy of Sciences
- Depression Linked to Bone-Thinning in Premenopausal Women
- BrainStorm Cell Therapeutics' Adult Stem Cell Approach More Relevant Than Embryonic Stem Cell Therapies
- Abbott to Present Comprehensive Safety and Efficacy Data on XIENCE V Drug Eluting Stent to FDA Advisory Committee on Nov. 29
- Amicus Therapeutics to Host R&D Day
November 28, 2007
- Transport's Phase 2 Data Show Single Treatment SoloVir ETS Significantly Stops Progression of Cold Sore Episode
- Preclinical Data on ARIAD's Multi-Targeted Kinase Inhibitor to Be Presented at ASH Annual Meeting
- Antares Pharma and Population Council Announce Phase I Results
- Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial
- Manhattan Pharmaceuticals Announces Positive Clinical Results for Hedrin in Treatment of Head Lice
- Promising Data ATIR Studies Presented by NIH Investigators
- Transport's Phase 2 Data Show Single Treatment SoloVir ETS Significantly Stops Progression of Cold Sore Episode
- OXiGENE's Zybrestat Reported to Have Anti-Leukemic Effects in Preclinical Studies Published in Blood
- Immutep Announces Positive Interim Results From a Study of Immufact IMP321 in Metastic Breast Cancer
- Nymox Announces Positive Results in New 2 Year Blinded, Placebo Controlled Study of NX-1207 for Benign Prostatic Hyperplasia
- Anavex Advances Drug Candidate for Treatment of Alzheimer's Disease
- Stallergenes: Oralair Grasses: Positive Results of VO52.06 Paediatric Study
- St. Jude Researchers Identify Key Genetic Trigger of Acute Myeloid Leukemia
- Thomson Scientific Takes a Fresh Look at Multiauthor Papers
- High Blood Pressure May Heighten Effects of Alzheimer's Disease
- Sirtris and Harvard Unveil Promising, Novel SIRT1 Activators for Treating Diseases of Aging; Therapeutic Type 2 Diabetes Data Published in the Journal Nature
- High-Trauma Fractures in Older Men and Women Linked to Osteoporosis
November 29, 2007
- Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkin's Lymphoma Patients
- Pharmacyclics Announces Presentations on Its Novel BTK and HDAC Inhibitors at the American Society of Hematology 49th Annual Meeting
- Osteoporosis: An Equal Opportunity Illness
- CVBT to Present Disc Ischemia Preliminary Results at World Forum for Spine Research Kyoto Meeting
- First European Patient Treated in CABERNET Trial With Novel Treatment for Wet AMD
- Three Astex Drug Candidates to be Presented at the 2007 American Society of Hematology Annual Meeting
- Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
- CytRx Phase IIa Open-Label Arimoclomol Data to Be Presented at the 18th International Symposium on ALS/MND
- Thallion Demonstrates ECO-4601 Crosses the Blood Brain Barrier and Selectively Targets Brain Tumours
- Bavarian Nordic A/S Reports Positive Data from First EUA Enabling Study with Imvamune Smallpox Vaccine
- Forest Laboratories, Inc. Announces Positive Results of Lexapro Phase III Study in Adolescents With Major Depression
- Aida Announces Completion of Anti-Cancer Drug Phase Two Testing
- Published Data Suggest That Erbitux Enables Complete Surgical Resection of Colorectal Liver Metastases in Patients Previously Refractory to Conventional Systemic Therapy
- Gloucester Pharmaceuticals Announces Presentation of Romidepsin Data at 2007 American Society of Hematology (ASH) Annual Meeting
- ImmunoGen, Inc. to Host Conference Call to Review Clinical Findings Reported at ASH
- Symptomatic Menopause Highlighted in Evidence-based Clinical Overview
November 30, 2007
- Chroma to Present Phase I Efficacy Data for Novel Cancer Therapy CHR-2797
- Alpharma's Phase III Pivotal Clinical Placebo-Controlled Trial of Its Abuse-Deterrent, Extended-Release Opioid Demonstrates Significant Efficacy
- Biological Psychiatry Publishes Study Showing Vyvanse Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
- Bionovo Describes a New Class of Therapeutic Compounds
- Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
- Crucell Presents Indian Phase I Rabies Antibody Cocktail Study, Positive Results Enable Prompt Progression Towards Phase II Studies
- Forest Laboratories and Lundbeck announces positive results of Lexapro phase III study in adolescents with major depression
- Bavarian Nordic Reports Positive Data from First EUA Enabling Study with IMVAMUNE Smallpox Vaccine Candidate
- Biological Psychiatry Publishes Study Showing Vyvanse Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
- Avexa's ATC Demonstrates Activity Against Emerging Class Resistance
